Nocutil (Desmopressin Acetate)

Desmopressin acetate, the active ingredient in Nocutil, is a vasopressin (antidiuretic hormone) analog presented as a nasal spray for nasal use. It treats central diabetes insipidus, nocturnal enuresis, and certain bleeding disorders such as mild hemophilia A and type 1 von Willebrand disease in appropriate patients.

GNH USA supplies Nocutil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acetate acts on the antidiuretic hormone pathway to control water balance and coagulation factors. - Central diabetes insipidus: reduces excessive urine output by increasing renal water reabsorption. - Nocturnal enuresis: decreases nighttime bedwetting episodes through antidiuretic action. - Hemophilia A (mild): raises factor VIII levels to improve clotting. - von Willebrand disease (type 1): increases von Willebrand factor to reduce bleeding.

Desmopressin nasal spray may cause a range of adverse reactions.

Common Side Effects: - Nasal irritation or congestion. - Headache. - Mild hyponatraemia. - Thirst. - Nausea.

Serious or Rare Side Effects: - Severe hyponatraemia leading to seizures. - Water intoxication. - Allergic reactions such as rash or angioedema. - Hypertension. - Pulmonary oedema.

Desmopressin requires careful clinical monitoring to minimise risks. - Dose adjustment: required in patients with renal impairment. - Fluid restriction: limit excessive water intake to reduce hyponatraemia risk. - Electrolyte monitoring: check serum sodium regularly during therapy. - Contraindications: avoid in patients with existing hyponatraemia or SIADH. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Desmopressin can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce desmopressin’s antidiuretic effect. - NSAIDs (e.g., ibuprofen): may increase risk of hyponatraemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may potentiate water retention. - SSRIs (selective serotonin reuptake inhibitors): may increase hyponatraemia risk. - ACE inhibitors: may enhance antidiuretic activity and fluid balance changes.